Literature DB >> 9300044

Novobiocin inhibits vaccinia virus replication by blocking virus assembly.

J Sekiguchi1, S Shuman.   

Abstract

Novobiocin inhibits the replication of vaccinia virus in cultured BSC40 cells. All classes of viral proteins were synthesized during synchronous infection in the presence of drug. The onset of DNA replication was delayed slightly, yet the extent of DNA replication in the presence of novobiocin was comparable to that of a control infection. A delay in the temporal transition to late viral protein synthesis was in keeping with the effects on DNA replication. Although the precursor forms of the major viral structural proteins were synthesized normally at late times, the proteolytic processing of these polypeptides was inhibited, which suggested an impediment to virus assembly. Electron microscopy revealed that novobiocin blocked virus morphogenesis at an early stage. Conversion of the concatemeric DNA replication intermediates into hairpin telomeres occurred in the presence of novobiocin, confirming that telomere resolution was not coupled to virus assembly. Novobiocin is the latest addition to a class of antipoxviral agents, which includes rifampin and IMCBH, that arrest morphogenesis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9300044     DOI: 10.1006/viro.1997.8684

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  10 in total

Review 1.  Orthopoxvirus targets for the development of antiviral therapies.

Authors:  Mark N Prichard; Earl R Kern
Journal:  Curr Drug Targets Infect Disord       Date:  2005-03

Review 2.  Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections.

Authors:  E De Clercq
Journal:  Clin Microbiol Rev       Date:  2001-04       Impact factor: 26.132

3.  The E6 protein from vaccinia virus is required for the formation of immature virions.

Authors:  Olga Boyd; Peter C Turner; Richard W Moyer; Richard C Condit; Nissin Moussatche
Journal:  Virology       Date:  2010-02-08       Impact factor: 3.616

4.  The major core protein P4a (A10L gene) of vaccinia virus is essential for correct assembly of viral DNA into the nucleoprotein complex to form immature viral particles.

Authors:  R Heljasvaara; D Rodríguez; C Risco; J L Carrascosa; M Esteban; J R Rodríguez
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

Review 5.  Broad action of Hsp90 as a host chaperone required for viral replication.

Authors:  Ron Geller; Shuhei Taguwa; Judith Frydman
Journal:  Biochim Biophys Acta       Date:  2011-12-02

6.  Molluscum contagiosum virus topoisomerase: purification, activities, and response to inhibitors.

Authors:  Y Hwang; B Wang; F D Bushman
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

7.  Identification of novel antipoxviral agents: mitoxantrone inhibits vaccinia virus replication by blocking virion assembly.

Authors:  Liang Deng; Peihong Dai; Anthony Ciro; Donald F Smee; Hakim Djaballah; Stewart Shuman
Journal:  J Virol       Date:  2007-10-10       Impact factor: 5.103

8.  Therapeutic and prophylactic drugs to treat orthopoxvirus infections.

Authors:  Scott Parker; Lauren Handley; R Mark Buller
Journal:  Future Virol       Date:  2008-11       Impact factor: 1.831

Review 9.  Orthopoxvirus targets for the development of new antiviral agents.

Authors:  Mark N Prichard; Earl R Kern
Journal:  Antiviral Res       Date:  2012-03-08       Impact factor: 10.103

10.  Dual inhibitors of SARS-CoV-2 proteases: pharmacophore and molecular dynamics based drug repositioning and phytochemical leads.

Authors:  Kartik Mitra; Prasanth Ghanta; Sushank Acharya; Gayathri Chakrapani; Basavaraju Ramaiah; Mukesh Doble
Journal:  J Biomol Struct Dyn       Date:  2020-07-22
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.